European Investment Bank

EQS-News: Marinomed Biotech AG announces results for the 2023 financial year and reports progress with Marinosolv and Carragelose assets

Retrieved on: 
fredag, maj 3, 2024
European Investment Bank, CFO, EIB, P&G, News, Map, Area studies, Partnership, Growth, EUR, BofA Securities, Cough, Research, Immunology, Clinical trial, Cryptocurrency

Cash and cash equivalents decreased to EUR 2.6 million (2022: EUR 8.2 million), with no major financing cash-inflows in the 2023 financial year contributing to the cash position.

Key Points: 
  • Cash and cash equivalents decreased to EUR 2.6 million (2022: EUR 8.2 million), with no major financing cash-inflows in the 2023 financial year contributing to the cash position.
  • “In 2023, we made important progress for both our Marinosolv and Carragelose assets.
  • However, the commercialization process for our Marinosolv assets takes longer than expected, causing Marinomed to fall short of expectations,” Andreas Grassauer, CEO of Marinomed, comments.
  • Our focus now is on near-term cash generation, including further license deals for Budesolv and expanding our Carragelose business.

Italy Construction Industry Report 2024: Market to Contract by 8.6% in Real Terms in 2024, and 2.8% in 2025 - Forecasts to 2028 - ResearchAndMarkets.com

Retrieved on: 
onsdag, maj 1, 2024
Other Construction & Property, Residential Building & Real Estate, Construction & Property, European Investment Bank, EIB, Construction, Investment, Safety, Risk, Commercial, Yoy, Sector, Growth, Autostrade of Italy, Assessment, National Institute of Statistics, ASPI

The "Italy Construction Market Size, Trends, and Forecasts by Sector - Commercial, Industrial, Infrastructure, Energy and Utilities, Institutional and Residential Market Analysis, 2024-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Italy Construction Market Size, Trends, and Forecasts by Sector - Commercial, Industrial, Infrastructure, Energy and Utilities, Institutional and Residential Market Analysis, 2024-2028" report has been added to ResearchAndMarkets.com's offering.
  • Historical (2019-2023) and forecast (2024-2028) valuations of the construction industry in Italy, featuring details of key growth drivers.
  • Analysis of the mega-project pipeline, including breakdowns by development stage across all sectors, and projected spending on projects in the existing pipeline.
  • Assess market growth potential at a micro-level with over 600 time-series data forecasts.

Italy Data Center Market Investment Analysis Report 2024: $3.83 Billion Growth Opportunities in IT, Electrical, Mechanical Infrastructure, General Construction, and Tier Standards to 2029 - ResearchAndMarkets.com

Retrieved on: 
måndag, april 29, 2024
Data Management, Technology, Other Construction & Property, Manufacturing, Construction & Property, Networks, Other Manufacturing, European Investment Bank, DBA, Investment, TIM, City, Equinix, BofA Securities, ISG, Artificial intelligence, Microsoft, AECOM, Gruppo TIM, Growth, Engineering, Renewable energy

The Italy data center market is expected to reach a value of $3.83 billion by 2029 from $3.03 billion in 2023, growing at a CAGR of 3.98%

Key Points: 
  • The Italy data center market is expected to reach a value of $3.83 billion by 2029 from $3.03 billion in 2023, growing at a CAGR of 3.98%
    This report analyses the market share of Italy's data center.
  • Some critical investors in the Italy data center market include Aruba, DATA4, Equinix, Telecom Italia, IRIDEOS, and STACK Infrastructure.
  • The Italy data center market also witnessed the entry of colocation operators such as Compass Datacenters and Vantage Data Centers.
  • A detailed study of the existing Italy data center market landscape, an in-depth market analysis, and insightful predictions about market size during the forecast period.

Median Technologies Reports Full-year 2023 Financial Results and Provides First Quarter 2024 Financial Information

Retrieved on: 
torsdag, april 25, 2024
Biometrics, Radiology, Biotechnology, Oncology, Health, Medical Devices, Health Technology, Clinical Trials, Contract research organization, European Investment Bank, FDA, EIB, United, Stand-alone, Traction, Partnership, BofA Securities, Cave rescue, Artificial intelligence, Growth, ChromeOS, MRMC, LCS, CSF, Bank statement, AUC, Cancer, CE

Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, “Median” or the “Company”) today reported its 2023 consolidated annual financial results, as of December 31, 2023, and provided financial information (unaudited) for the first quarter of 2024, as of March 31, 2024.

Key Points: 
  • Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, “Median” or the “Company”) today reported its 2023 consolidated annual financial results, as of December 31, 2023, and provided financial information (unaudited) for the first quarter of 2024, as of March 31, 2024.
  • The consolidated financial statements for the financial year ended December 31, 2023, were audited and approved by the Company’s Board of Directors on April 24, 2024.
  • In Quarter 1, our revenues were impacted by the postponement to Quarter 2 of some studies due to late patient recruitment.
  • Consistent with the long-lasting partnership between CSF and Median, this agreement strengthens the future relationship between CSF and Median.

Acre Impact Capital Announces the First Closing of its Export Finance Fund I

Retrieved on: 
onsdag, april 17, 2024
Finance, Consumer, Alternative Energy, Energy, Professional Services, Other Philanthropy, Philanthropy, Environment, Sustainability, Fund Raising, Foundation, Women, Green Technology, Climate Change, European Investment Bank, City, Transport, Investment, Woman, SURE, Food, Development aid, Social, Primary energy, BofA Securities, Rail transport by country, Culture, International development, Fund, ECA, USAID, Financial services

Acre Impact Capital , a private-debt impact investment manager announces the first closing of its Export Finance Fund I (the “Fund”), with commitments of ~US$100mn, with a target size of US$300mn.

Key Points: 
  • Acre Impact Capital , a private-debt impact investment manager announces the first closing of its Export Finance Fund I (the “Fund”), with commitments of ~US$100mn, with a target size of US$300mn.
  • The Fund has also secured significant commitments from several African investors, reflecting the attractive risk-return profile and expected impact of the strategy.
  • Acre Impact Capital’s innovative Export Finance Fund I is the first fund of its kind leveraging the transaction facilitation role of export credit agencies (“ECAs”) for impact.
  • “We are incredibly proud to have received support from our limited partners, who have backed our pioneering Export Finance Fund I.

EQS-News: Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement

Retrieved on: 
onsdag, april 10, 2024
EIB, Peripheral nervous system, Patient, CNS, Schizophrenia, XETRA, European Investment Bank, BofA Securities, Pharmaceutical industry

Under the amendment, repayment of tranches one to three (out of a total of five) of the financing agreement with due dates from June 2024 to April 2025 will be shifted substantially, with tranche one now scheduled for November 25, 2025, tranche two for April 2026 and tranche three for June 2026.

Key Points: 
  • Under the amendment, repayment of tranches one to three (out of a total of five) of the financing agreement with due dates from June 2024 to April 2025 will be shifted substantially, with tranche one now scheduled for November 25, 2025, tranche two for April 2026 and tranche three for June 2026.
  • The due dates for tranches four and five will stay unchanged.
  • On the amended tranches, Newron will start paying the agreed interest rates.
  • Details of the 2018 loan agreement can be found in Newron’s 2022 Annual Report which is posted on its website.

EQS-News: Marinomed Biotech AG announces agreement with European Investment Bank (EIB) to defer repayments of the 2019 venture loan for 18 months

Retrieved on: 
onsdag, april 10, 2024
Procter & Gamble, EIB, EUR, CFO, Virology, European Investment Bank, BofA Securities, Credit

Under the amendment, repayment of tranche one with a nominal value of EUR 4 million will be shifted from October 2024 to April 2026.

Key Points: 
  • Under the amendment, repayment of tranche one with a nominal value of EUR 4 million will be shifted from October 2024 to April 2026.
  • Tranche two, with a nominal value of EUR 5 million, will be shifted from December 2025 to June 2027.
  • The amendment contains further terms and conditions, including the extension of the existing royalty agreement for five years.
  • The lenders of the real estate financing also agreed to suspend their capital repayments alongside with the EIB.

Powerful Medical's AI Breakthrough Marks a New Dawn in Heart Attack Diagnostics with EIC Support Doubles Sensitivity in Identifying Acute Coronary Occlusion on 12-Lead ECG

Retrieved on: 
måndag, mars 18, 2024
European Innovation Council, Longevity, Medicine, Cardiology, Patient, Splenic infarction, MD, EIC, Accelerator, European Investment Bank, Heart, EIB, FDA, Health, Medical device

With a landmark advancement in medical diagnostics, Powerful Medical has distinguished itself within the competitive digital health landscape.

Key Points: 
  • With a landmark advancement in medical diagnostics, Powerful Medical has distinguished itself within the competitive digital health landscape.
  • At the core of its mission, Powerful Medical introduces the PMcardio platform, a CE-certified medical device leveraging proprietary AI to analyze electrocardiograms (ECGs) with remarkable precision.
  • This platform is capable of diagnosing heart attacks — specifically, occlusion myocardial infarctions — significantly earlier and with double the sensitivity compared to the current standard of care.
  • - Robert Herman, MD, Chief Medical Officer
    As Powerful Medical begins its Series A fundraising, the EIC Accelerator's grant and investment endorse the company's vision and technology.

Inventiva reports its 2023 full-year results

Retrieved on: 
onsdag, mars 27, 2024
DSM-IV codes, NMPA, Acceleration, Partnership, Patient, Income tax, G&A, BofA Securities, MASH, Equity, SUSAR, IND, Marketing, Bank statement, IRB, Clinical trial, Investigational New Drug, European Investment Bank, Fatty liver disease, Type 2 diabetes, T2D, Euronext Paris, EIB, Phase, Optimism, NAFLD, Sino Biopharmaceutical Limited, Pharmaceutical industry

Frédéric Cren, Chairman, CEO and cofounder of Inventiva, stated: “Inventiva achieved several clinical and financial milestones in 2023.

Key Points: 
  • Frédéric Cren, Chairman, CEO and cofounder of Inventiva, stated: “Inventiva achieved several clinical and financial milestones in 2023.
  • R&D expenses for the fiscal year ended December 31, 2023, amounted to (€110.0) million compared to (€60.5) million in 2022.
  • Net financial income was (€5.1) million for the fiscal year ended December 31, 2023, compared to €2.8 million in 2022.
  • Income tax amounted to (€0.6) million for the 2023 fiscal year, compared to €0 million for 2022.

OpGen Announces Acquisition of Preferred Stock by David Lazar

Retrieved on: 
måndag, mars 25, 2024
Common stock, BofA Securities, Doctor of Philosophy, European Investment Bank, EIB, Trustee, Corporate development, Curetis, Corporation

On March 25, 2024, Mr. Lazar paid $200,000 at the initial closing of the transactions in exchange for 200,000 shares of Series E Preferred Stock.

Key Points: 
  • On March 25, 2024, Mr. Lazar paid $200,000 at the initial closing of the transactions in exchange for 200,000 shares of Series E Preferred Stock.
  • Each share of Series E Preferred Stock is convertible into 24 shares of the Company’s common stock (“Common Stock”).
  • The conversion of the Series E Preferred Stock into shares of common stock in excess of applicable statutory and regulatory thresholds, including national stock exchange rules, will be subject to receipt of stockholder approval for the issuance of such shares of Common Stock.
  • We believe the transaction also offers future opportunities for OpGen stockholders to participate in possible future strategic transactions under the leadership of David Lazar and the new members of the board.